123 Main Street, New York, NY 10001

Top Navigation with Mega Menu

Co-Dx Executive Leadership

Meet the people bringing the Power to Know™ to the world

Dwight H. Egan, Chief Executive Officer

Mr. Dwight Egan has been an officer and director since April 2013. Mr. Egan has been engaged in the private investment business from February 1999 to the present. He was a senior executive at Data Broadcasting Corporation, a leading provider of wireless, real-time financial market data, news, and sophisticated fixed-income portfolio analytics to 27,000 individual and professional investors from 1995 to 1999. He co-founded and served as CEO and Chairman of the Board of Broadcast International, Inc. from 1984 to 1995 when Data Broadcasting Corporation acquired Broadcast International and created CBS MarketWatch, a leading financial news site, and participated in its initial public offering. Mr. Egan’s prior experience in directing a public company and working with capital markets gives him valuable experience in advising the board on matters of finance and operations.

Richard Abbott, President​

Richard Abbott has over 25 years in senior leadership positions in in vitro diagnostics that include developing systems for infectious disease diagnosis, food pathogen monitoring, biological weapons threat detection for military and first responders, and genetics research for pharmaceutical companies and universities. As Vice President of Engineering at BioFire Diagnostics, Richard built and led highly effective cross-functional teams that developed and sold billions of dollars in revenue. Mr. Abbott holds a Master of Science degree in mechanical engineering from Brigham Young University and an M.B.A. from the Wharton Business School.

Brian L. Brown, CPA, Chief Financial Officer

Mr. Brian L. Brown was appointed Chief Financial Officer in February 2021. Previously, he served as Chief Financial Officer of A-Core Concrete Cutting, Inc., a privately held specialty construction company, and was Vice President of Accounting, Treasury & Investor Relations, in addition to Director of Finance, for Sportsman’s Warehouse Holdings, Inc. (Nasdaq: SPWH), a publicly traded outdoor sporting goods retailer. Prior to becoming a Certified Public Accountant in 2007, Mr. Brown received his Master of Professional Accountancy (MPrA) degree from the University of Utah David Eccles School of Business in 2001 and a Bachelor of Arts Degree in Accounting from the University of Utah in 2000. Mr. Brown’s experience in finance, accounting, and roles directing successful financial departments all help make Mr. Brown a critical component of the Co-Diagnostics leadership team.

David Nielsen, Chief Operations Officer​

David Nielsen joined Co-Dx in January 2022 with the acquisition of Advanced Conceptions, Inc. He has more than 25 years of R&D technical and leadership experience primarily at BioFire and BioFire Defense (formerly Idaho Technology), which was purchased by bioMérieux in 2014. As one of the original Idaho Technology employees, Mr. Nielsen worked in various roles in engineering, management, and business development. Mr. Nielsen holds a BS degree in Mechanical Engineering from Brigham Young University and both a MS in Mechanical Engineering and MBA from the University of Utah

Ivory Chang, Chief Regulatory Affairs Officer

Ms. Chang was appointed Chief Regulatory Affairs in August 2023. Previously, she served as Sr. Director of Regulatory Affairs and Clinical Affairs at Thermo Fisher Scientific, where she led the global registration strategy, including the US FDA for the various PCR and sequencing platforms. Ms. Chang has spent 16 years working on infectious disease and cancer diagnostics. Lately, Ms. Chang has been actively involved in new AI/ML software regulations and led BARDA program for Danaher’s new diagnostic platform in 2020. Ms. Chang also led regulatory development and strategies for RUO reagents, instruments, and LDT as Regulatory Director at Agilent Technology and Genomic Health. Prior to specializing in IVD regulations, Ms. Chang acquired many years of 510k and PMA submission experience for traditional cardiovascular medical devices. Ms. Chang’s expertise in in vitro diagnostics (IVD) and medical device regulations is critical in navigating the complex global regulatory environment for Co-Diagnostics’ current and future product roadmap in the endemic era.

Ms. Chang received her undergraduate degree in Microbiology from Taiwan and her postgraduate degree in Advanced Instrumentation Systems from University College London (UCL) in England, UK.

Christopher Thurston, Chief Technology Officer

Christopher Thurston came to Co-Dx™ as the co-founder of Idaho Molecular and co-inventor of the Co-Dx PCR Pro™. He is passionate about improving human quality of life and has been instrumental in democratizing PCR diagnostics. His tenure as the principal developer and architect behind BioMerieux’s SyndromicTrends.com underscores his commitment and expertise in developing big-data solutions that advance public health. With a distinguished career that includes serving as a senior architect at Ernst and Young, senior architect at BioFire Defense, as well as executive positions at several startups, he has consistently demonstrated exceptional strategic leadership and a knack for technological innovation across a variety of sectors.

Additionally, Christopher served his country in the Army as part of the Operations in the Middle East. His military background, as well as his time living in France, has influenced his approach to the tech and biotech industries, imbuing him with a unique perspective that human health is a global problem that requires global solutions.

Seth Egan, Chief Commercialization Officer

Seth is a co-founder of Co-Diagnostics, Inc. and has led the company’s sales, marketing, and product commercialization efforts since its inception. With over 12 years of experience in the diagnostics field, Seth has played a key role in executive management of the company, including: company operations, financings, product introductions and managing (with Mohal Sarabhai) the Co-Dx/CoSara JV relationship between Co-Dx and India’s Symbiotics, LTD.

Seth participated in organizing the company’s IPO and subsequent financings. Under his guidance and in collaboration with a dedicated sales team, Co-Dx has distributed more than 35M tests to more than 50 countries, generating over $200M in revenue since 2020. Seth supervises all sales and marketing events for the company worldwide. He is eager to see the new Co-Dx PCR Pro platform make a significant impact by providing PCR tests worldwide, to both developed and emerging nations. Seth has a Bachelor of Science degree from Utah Valley University, where he majored in Business Communications.

International Operations

Mayuranki Almaula, Ph.D., Sr. VP Overseas Operations and Strategic Alliances

Dr. Mayuranki Almaula is responsible for establishing clinical verification and validation strategies that support our diagnostic portfolios. This involves supporting the India-based clinical and manufacturing operations for our joint venture, CoSara Diagnostics Pvt Ltd. Dr. Almaula has provided support in establishing relationships across multiple continents for companies including Insilico Sciences, as Business Development Director, Gen Probe (now Hologic), as supporting the Senior Executive VP of Business Development in defining and executing their India strategy, and Symbiosis Biowares in their International Business Development strategy. Mayuranki completed a Master’s in Microbiology from Maharaja Sayajirao University Baroda and a doctorate in Microbiology from Stanford University.